Summary of West Pharmaceutical Services Conference Call Company Overview - **Company**: West Pharmaceutical Services (NYSE: WST) - **Industry**: Life Sciences, specifically focusing on drug delivery and containment solutions Key Points and Arguments Business Model and Market Position - West has a strong market share of **70%-75%** in its industry, with significant opportunities in biologics, which are expected to increase participation rates further [3][4] - The company has a durable business model with a competitive moat, as it typically retains contracts for the life of the product once specified [3][4] 2025 Performance and Transition - 2025 was characterized as a transitional year, with significant progress made in various areas, including GLP-1s and core business operations [7][9] - The company exited 2025 with strong momentum, exceeding expectations, particularly in non-GLP-1 business where demand outstripped supply [9] 2026 Guidance - West is guiding for **5%-7%** top-line growth in 2026, with the majority of this growth expected from the non-GLP-1 business [11][12] - The non-GLP-1 business is projected to grow at a high single-digit to low double-digit rate, driven by strong demand and capacity expansion [18][47] - GLP-1 growth is conservatively estimated at **10%**, down from **50%** growth in 2025, reflecting a more cautious outlook due to market dynamics [11][12][13] Drivers of Growth - The company is experiencing stronger demand than supply, particularly in the non-GLP-1 segment, and is ramping up capacity in its German plant [18][19] - Annex 1 regulations are expected to contribute an additional **200 basis points** to growth in 2026, as companies upgrade to high-value products [20][22] - The participation rate for biologics is over **90%**, indicating strong market engagement and potential for future growth [19][43] Biosimilars and Generics - Biosimilars are included in the revenue projections, with the company seeing a shift from branded to biosimilar products without a significant downgrade in economics [43][44] - There is potential for growth in generic GLP-1s as patents expire in various markets, with modest expectations built into the 2026 numbers [45][56] Capital Expenditure and Capacity - The capital expenditure forecast for 2026 is between **$250-$275 million**, with **40%** allocated for maintenance and **60%** for growth [61] - The company is focused on onshoring opportunities and tech transfers to enhance capacity and support customer needs [62][63] Market Trends and Future Outlook - The company anticipates ongoing demand for both auto-injectors and multi-dose pens, indicating a dual growth strategy rather than a choice between the two formats [70][72] - Discussions with major partners like Lilly are ongoing to align capacity with future demand, emphasizing the importance of early engagement in demand planning [74][75] Additional Important Insights - The company is well-positioned to benefit from regulatory changes and market dynamics, with a multi-year growth outlook rather than a one-time opportunity [23][35] - The transition to higher-value products is expected to create a multiplier effect on revenue, enhancing overall business performance [23][35] This summary encapsulates the key insights from the conference call, highlighting West Pharmaceutical Services' strategic positioning, growth outlook, and market dynamics.

Summary of West Pharmaceutical Services FY Conference Call Company Overview - **Company**: West Pharmaceutical Services (NYSE: WST) - **Date of Conference**: March 10, 2026 - **Key Speakers**: Eric M. Green (CEO), Robert McMahon (CFO) Core Industry Insights - **Industry**: Life Sciences Tools and Diagnostics - **Market Trends**: - Significant growth in GLP-1 (glucagon-like peptide-1) products - Rise of biologics and biosimilars - Onshoring effects in North America, enhancing local manufacturing capabilities - Transition from IV to subcutaneous (subQ) delivery methods, with a focus on auto-injectors and multi-dose pens [6][8][33] Strategic Direction - **CEO Transition**: Eric M. Green announced his intent to retire, emphasizing the importance of a smooth transition to a new CEO [2][3] - **Leadership Team**: Strong executive leadership team in place, with a focus on maintaining operational strength during the transition [3][4] - **Growth Drivers**: - Participation in over 90% of new biologic approvals - Critical role in the GLP-1 market, supporting multiple delivery modalities [9][10][11] Financial Performance and Guidance - **Growth Expectations**: - Anticipated revenue growth of 5%-7% for 2026, primarily driven by High-Value Products (HVP) [38] - GLP-1 products expected to grow at a rate higher than the company average, with a conservative estimate of 10% growth [39] - **Margin Expansion**: Expected margin expansion of over 100 basis points, aided by product mix and operational efficiencies [42] Manufacturing and Capacity - **Manufacturing Footprint**: - 25 manufacturing plants globally, with significant capacity for HVP components [8] - Recent bottlenecks in the German plant due to labor issues, now being addressed [22][23] - **Capital Expenditures**: - Planned capital expenditures of 6%-8% of sales, focusing on growth-oriented investments [28][32] Market Dynamics - **Biosimilars and Generics**: - Anticipated growth in the biosimilars market, particularly for GLP-1s in emerging markets like China and India [14][15] - **Regulatory Changes**: - Annex 1 regulations expected to drive demand for HVP components, with a significant portion of standard products transitioning to HVP [57][60] Challenges and Risks - **Supply Chain Issues**: - Previous supply-demand imbalances, particularly in Europe, are being managed with adjustments in lead times and production capacity [22][25] - **Approval Rates**: - Current low approval rates for new drugs may pose a short-term challenge, but long-term growth is expected to remain strong [61][70] Additional Insights - **Divestiture of SmartDose**: - Strategic decision to divest the SmartDose business to focus on larger market opportunities, with expected margin benefits from the sale [47][50] - **Innovation Focus**: - Continued investment in R&D to enhance the HVP portfolio and develop next-generation products [54][56] This summary encapsulates the key points discussed during the conference call, highlighting the strategic direction, market dynamics, and financial outlook for West Pharmaceutical Services.

Financial Data and Key Metrics Changes - The company reported fourth quarter revenues of $805 million, representing a 7.5% increase on a reported basis and a 3.3% increase organically [9][18] - Adjusted EPS for the fourth quarter was $2.04, up 12% compared to the prior year [9][23] - Free cash flow in the fourth quarter was $175 million, more than double the prior year level, contributing to a full year free cash flow of $469 million, up 70% year-on-year [6][24] Business Line Data and Key Metrics Changes - HVP components, representing 48% of total net sales, grew over 15% in the fourth quarter and 9% for the full year of 2025 [10][19] - HVP delivery devices, accounting for 14% of sales, saw a decline of 18.1% year-over-year organically due to a prior year incentive payment [11][20] - Standard products, which represent 20% of the business, declined 1.7% on an organic basis during the fourth quarter [11][21] - Contract manufacturing revenues increased 1.9% organically in Q4, driven by self-injected devices for obesity and diabetes [11][21] Market Data and Key Metrics Changes - The company noted strong demand for high-value product components driven by the rise of biologics and biosimilars, as well as increasing global regulatory requirements [7][12] - The Annex 1 upgrades represent a multiyear opportunity with over 700 projects initiated, with more than half completed and generating revenues [14][81] Company Strategy and Development Direction - The company aims to leverage growth drivers such as biologics, Annex 1, and GLP-1s to advance its strategies in 2026 [12][18] - The launch of the West Synchrony Prefillable Syringe System is a significant step in drug delivery solutions, designed specifically for biologics [7][73] - The company is focused on organic growth while considering potential acquisitions that could enhance its high-value product components [39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering 2026 with momentum, expecting organic revenue growth of 5%-7% and adjusted EPS growth of 10% at the midpoint of guidance [18][29] - The company anticipates continued improvement in the injectable market throughout 2026, driven by underlying trends [25][29] Other Important Information - The company expects to close the SmartDose transaction mid-year, which will impact revenue guidance for 2026 [25][26] - Capital expenditures for the year were $286 million, down $91 million year-on-year, with expectations for further reductions in 2026 [24] Q&A Session Questions and Answers Question: Insights on GLP-1 customer demand and guidance conservatism - Management indicated no changes in customer behavior and characterized the initial guidance as conservative, emphasizing strength in the business beyond GLP-1s [35][36] Question: Potential for M&A or share buybacks - Management confirmed that capital deployment priorities remain focused on organic growth, but they are open to technologies that could enhance their portfolio [39][40] Question: Demand outstripping supply in HVP components - Management acknowledged that demand continues to outpace supply, with ongoing capacity expansion to meet this demand [42][44] Question: Clarification on GLP-1 growth assumptions - Management noted that GLP-1s grew in excess of 50% in 2025, while non-GLP-1s were roughly flat, with expectations for acceleration in 2026 [78] Question: Details on Annex 1 cycle upgrades - Management highlighted that less than 15% of the 6 billion components opportunity has been commercialized, viewing it as a multiyear journey [14][81]

Financial Data and Key Metrics Changes - The company reported Q4 revenues of $805 million, representing a 7.5% increase year-over-year and a 3.3% organic growth [9][18] - Adjusted EPS for Q4 was $2.04, up 12% compared to the prior year [9][23] - Free cash flow in Q4 was $175 million, more than double the prior year level, contributing to a full-year free cash flow of $469 million, up 70% year-over-year [6][24] Business Segment Data and Key Metrics Changes - HVP components, representing 48% of total net sales, grew over 15% in Q4 and 9% for the full year of 2025 [10][19] - HVP delivery devices, accounting for 14% of sales, saw a decline of 18.1% year-over-year in Q4 due to a prior year incentive payment [11][20] - Standard products declined 1.7% on an organic basis in Q4, while contract manufacturing revenues increased 1.9% organically [11][21] Market Data and Key Metrics Changes - The company noted strong demand for high-value product components driven by the rise of biologics and biosimilars, as well as increasing global regulatory requirements [7][12] - The GLP-1 market is expected to continue supporting growth, with the adoption of GLP-1s still in early stages [15][17] Company Strategy and Development Direction - The company aims for 5%-7% organic revenue growth in 2026, with adjusted EPS growth of 10% at the midpoint of guidance [18][29] - A comprehensive evaluation of the SmartDose business led to its sale, aligning with the company's focus on patient-centric approaches for large on-body delivery devices [8] - The company is expanding its capacity in Dublin for drug handling, which is expected to ramp up throughout 2026 [8][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth strategy, highlighting the effectiveness of their execution and the momentum entering 2026 [6][30] - The company anticipates continued improvement in the injectable market throughout 2026, with a focus on high-value products [25][29] Other Important Information - The company completed 65 Annex 1 projects in Q4 2025, with over 700 projects initiated, indicating strong progress in regulatory compliance [14][80] - The company expects to close the SmartDose transaction mid-year, impacting future revenue guidance [25][29] Q&A Session Summary Question: Insights on GLP-1 customer demand and guidance conservatism - Management noted no changes in customer behavior and characterized the initial guidance as conservative, emphasizing strength beyond GLP-1s [35][36] Question: Potential for M&A or share buybacks - Management indicated that while organic growth remains a priority, they are open to exploring technologies that could enhance their high-value product components [39][40] Question: Demand outstripping supply in HVP components - Management confirmed that demand continues to outpace supply, with ongoing capacity expansion to meet this demand [42][44] Question: Clarification on growth assumptions for HVP in 2026 - Management provided ranges indicating GLP-1s grew over 50% in 2025, while non-GLP-1s were roughly flat, expecting acceleration in 2026 [78]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenues of $805 million, representing a 7.5% increase on a reported basis and a 3.3% increase organically [8][17] - Adjusted EPS for the fourth quarter was $2.04, up 12% compared to the prior year [8][22] - Free cash flow in the fourth quarter was $175 million, more than double the prior year level, contributing to a full year free cash flow of $469 million, up 70% year-on-year [8][23] Business Segment Data and Key Metrics Changes - HVP components, representing 48% of total net sales, grew over 15% in the fourth quarter and 9% for the full year of 2025 [9][18] - HVP delivery devices, accounting for 14% of sales, saw a decline of 18.1% year-over-year organically, primarily due to an incentive payment received in the prior year [10][18] - Standard Products, which represent 20% of the business, declined 1.7% on an organic basis during the fourth quarter [10][18] - Contract manufacturing revenues increased 1.9% organically in Q4, driven by self-injected devices for obesity and diabetes [10][18] Market Data and Key Metrics Changes - The company noted strong demand for high-value product components driven by the rise of biologics and biosimilars, increasing global regulatory requirements, and the expanding GLP-1 market [5][11] - The company has initiated over 700 Annex 1 projects, with over half completed and generating revenues, representing less than 15% of the 6 billion components targeted for upgrades [12][80] Company Strategy and Development Direction - The company aims to leverage growth drivers such as biologics, Annex 1, and GLP-1s to advance its strategies and expects robust momentum entering 2026 [11][17] - The launch of the West Synchrony Prefillable Syringe System is a significant step in drug delivery solutions, designed specifically for biologics [5][72] - The company plans to continue investing in high-value product components while exploring potential technologies for inorganic growth [39][72] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth strategy, highlighting a strong order book and demand from biologic customers [42][59] - The company anticipates organic revenue growth of 5%-7% and adjusted EPS growth of 10% at the midpoint for 2026 [17][28] - Management remains cautious about GLP-1 growth, projecting a 10% increase year-on-year, which is considered conservative given the previous year's growth of over 50% [26][76] Other Important Information - The company expects to close the SmartDose transaction mid-year, which will impact revenue guidance for 2026 [24][25] - Capital expenditures for 2026 are expected to decrease to a range of $250 million-$275 million, reflecting a focus on efficiency [23][28] Q&A Session Summary Question: Insights on GLP-1 customer demand and guidance conservatism - Management indicated no changes in customer behavior and characterized the initial guidance as conservative, emphasizing strength in the overall business beyond GLP-1s [35][36] Question: Potential for share buybacks or M&A - Management confirmed that capital deployment will prioritize organic growth but remains open to technologies that could enhance the HVP components business [39][40] Question: Demand outstripping supply in HVP components - Management acknowledged that demand continues to outpace supply, particularly in the HVP components business, and is actively expanding capacity [42][43] Question: Clarification on new GLP-1 molecules and HVP components - Management noted that new GLP-1 molecules are expected to use similar elastomeric HVP components, with a mix of new combination molecules requiring proprietary technologies [46][49] Question: Progress on Annex 1 upgrades - Management stated that less than 15% of the 6 billion components have been commercialized, with expectations for continued revenue growth from these projects in 2026 [80]

Summary of West Pharmaceutical Services Q3 2025 Conference Call Company Overview - **Company**: West Pharmaceutical Services (NYSE: WST) - **Date of Conference**: November 11, 2025 Key Points Q3 Performance - The company reported a **5% organic growth** in Q3, exceeding guidance [5][6] - The **HVP (High-Value Products) component business**, which constitutes approximately **48%** of total business, achieved a **13.3% organic growth** [5][6] - Strong margins were noted, with earnings per share growth surpassing targets [5][6] - The performance in Q3 is seen as an acceleration from Q2, with expectations for continued growth into Q4 and 2026 [5][6] GLP-1 Market Insights - The GLP-1 category is highlighted as a significant therapeutic area for HVP components [7][20] - Non-GLP-1 revenue showed **mid-single-digit growth** in Q3, with expectations for a return to **high single-digit growth** in Q4 as destocking issues are resolved [13][19] - The company maintains a **90% participation rate** in new biologics products, indicating strong market presence [13][20] - The recent announcement by Eli Lilly and Novo Nordisk regarding pricing strategies is viewed positively, as it may increase access and sales volume for West [20][22] Biologics and Drug Delivery - The biologics business grew **8%** in Q3, with GLP-1s contributing to nearly half of this growth [30] - The SmartDose drug delivery device is under evaluation for its long-term position within the portfolio, with ongoing cost improvements [33][34] - The company is exploring opportunities in drug delivery devices, including SmartDose and other products [32][33] Regulatory Impact - The **Annex 1** regulation in Europe presents an opportunity to transition standard products to higher-value offerings, with an expected **200 basis points** revenue improvement [37][38] - The company has **371 active projects** aimed at upgrading products, with a potential market of **6 billion components** for conversion [38][46] Pricing Strategy - Pricing in Q3 was slightly below the target of **2-3%**, but the company remains optimistic about future pricing strategies [53][55] - A portfolio approach to pricing is being developed to enhance value and incentivize customers to shift to higher-value products [55][58] Contract Manufacturing - The company is actively seeking to replace approximately **$40 million** in lost CGM revenue by ramping up other programs, including drug handling [61][63] - The contract manufacturing business is seen as a way to provide more comprehensive services across the injectable continuum [64][66] Margin Improvement - Key drivers for margin improvement include product mix and pricing strategies, with expectations for at least **100 basis points** margin expansion through the end of the decade [70][71] - The company is focusing on optimizing production efficiency and logistics to enhance gross margins [68][70] Future Outlook - The company is optimistic about growth in the high-value component business, which is expected to continue into 2026 [80][82] - Destocking issues are largely resolved, and the company anticipates normalized ordering patterns moving forward [82] Strategic Considerations - The company is considering more deliberate capital allocation strategies, including potential M&A opportunities to enhance growth [72][73] - The launch of the **Synchrony S1 prefillable syringe** is seen as a significant opportunity to improve customer offerings [73][75] Conclusion West Pharmaceutical Services is positioned for continued growth, particularly in high-value components and biologics, with strategic initiatives in pricing, product development, and regulatory compliance expected to drive future performance. The company is actively addressing challenges while capitalizing on emerging opportunities in the market.

Financial Data and Key Metrics Changes - Revenues for Q3 2025 were $805 million, representing a 5% increase on an organic basis and a 7.7% increase on a reported basis [5][14] - Adjusted operating margins were 21.1%, while adjusted EPS was $1.96, up 6% compared to the prior year [5][17] - Year-to-date operating cash flow increased by 9% to $504 million, and free cash flow rose by 54% to $294 million [17] Business Line Data and Key Metrics Changes - Proprietary product segment revenues were $648 million, up 5.1% organically, driven by HVP components which saw a 13% organic growth [7][14] - HVP delivery device revenues declined by 16.7% year-on-year to $99 million, primarily due to a prior year incentive payment [10][14] - Contract manufacturing segment revenues were $157 million, growing by 4.9% organically [11][16] Market Data and Key Metrics Changes - Biologics revenue was $329 million, up 8.3% organically, while pharma revenue rose 1.4% to $183 million [15] - GLP-1 elastomers now account for 9% of total company sales, indicating strong growth in this area [8][44] Company Strategy and Development Direction - The company is increasing its guidance for 2025 due to strong performance and expects continued momentum in its business [6][18] - Focus on high-value product components, particularly in the GLP-1 and Annex 1 markets, is expected to drive future growth [21][46] - The company is actively working on optimizing its manufacturing network and enhancing operational efficiencies [77][80] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of growth in HVP components, driven by biologics and biosimilars [24][30] - The company anticipates a transition period in 2026 as it exits the CGM contract, but is optimistic about backfilling with higher-margin business [35][36] - Management highlighted the importance of maintaining strong relationships with customers to navigate market dynamics [66][81] Other Important Information - The company has appointed a new CFO and CTO to strengthen its leadership team and drive innovation [6][7] - The company is ramping up production in its Dublin facility, expecting to add approximately $20 million in revenue next year [12][56] Q&A Session Summary Question: Long-term growth prospects for 7% to 9% - Management believes they are on track to achieve long-term growth targets, driven by HVP components and biologics [24][25] Question: Sustainability of HVP components growth - Management is confident in the double-digit growth trajectory for HVP components, supported by strong order trends and market normalization [28][30] Question: Visibility on CGM contract exit - Management is engaged in discussions with potential customers to replace the CGM business, expecting healthy revenues and margins [35][36] Question: Margin opportunities - Management sees opportunities for margin expansion through operational efficiencies and higher-value product offerings [34][60] Question: Impact of Annex 1 on customer decisions - Management noted that increased regulatory conversations are accelerating project timelines and conversions related to Annex 1 [54][56]

Financial Data and Key Metrics Changes - Revenues for Q3 2025 were $805 million, representing a 5% increase on an organic basis and a 7.7% increase on a reported basis [5][14] - Adjusted operating margins were 21.1%, while adjusted EPS was $1.96, up 6% compared to the prior year [5][17] - Year-to-date operating cash flow reached $504 million, up 9%, and free cash flow was $294 million, a 54% increase from last year [17][18] Business Line Data and Key Metrics Changes - Proprietary product segment revenues were $648 million, up 5.1% organically, driven by HVP components, which saw a 13% organic growth [7][14] - HVP delivery device revenues declined to $99 million, down 16.7% year-on-year organically, primarily due to a prior year incentive payment [10][14] - Contract manufacturing segment revenues were $157 million, growing by 4.9% organically [11][15] Market Data and Key Metrics Changes - Biologics revenue was $329 million, up 8.3% organically, while pharma revenue rose 1.4% to $183 million [15] - GLP-1s accounted for 9% of total company sales, with strong growth expected to continue [8][12] - The company is experiencing a normalization in demand trends for biologics and biosimilars, with a participation rate above 90% year-to-date [8] Company Strategy and Development Direction - The company is increasing its guidance for 2025 due to strong performance and improving business momentum [5][18] - Focus on high-value product components, particularly in the GLP-1 and Annex 1 markets, is expected to drive future growth [21][46] - The company is actively working on optimizing its manufacturing network and consolidating operations to enhance efficiency [75][82] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of positive trends due to strong execution and improving market conditions [22][66] - The company anticipates that destocking is largely behind them, with demand expected to improve for key growth drivers [21][66] - There are ongoing discussions with customers regarding new business opportunities to replace the CGM contract expected to conclude in mid-2026 [35][36] Other Important Information - The company has appointed a new CFO and CTO to strengthen its leadership team and drive innovation [6][7] - The company is ramping up production in its Dublin facility for drug handling, expected to add approximately $20 million in revenue next year [12][56] Q&A Session Summary Question: Long-term growth outlook for 7%-9% - Management believes they are on track to achieve long-term growth targets, driven by HVP components and biologics [24][25] Question: Sustainability of HVP components growth - Management is confident in the sustainability of double-digit growth for HVP components, supported by GLP-1s and Annex 1 [28][30] Question: Visibility on CGM contract exit - Management is engaged in discussions with potential customers to fill the gap left by the CGM contract, expecting healthy revenues and margins [35][36] Question: Margin opportunities - Management sees opportunities for margin expansion through operational efficiencies and higher-value products [34][60] Question: Impact of Annex 1 on customer decisions - Annex 1 projects are accelerating, with more conversations with EU regulators, leading to increased customer interest [54][56] Question: Growth in GLP-1s - Management expects continued healthy growth in GLP-1s, driven by market dynamics and new approvals [42][45]

Financial Data and Key Metrics Changes - Revenues for Q3 2025 were $805 million, representing a 5% increase on an organic basis and a 7.7% increase on a reported basis [4][12] - Adjusted operating margins were 21.1%, while adjusted EPS was $1.96, up 6% compared to the prior year [4][16] - Year-to-date operating cash flow increased by 9% to $504 million, and free cash flow rose by 54% to $294 million [16] Business Line Data and Key Metrics Changes - Proprietary product segment revenues were $648 million, up 5.1% organically, driven by HVP components, which saw a 13% organic growth [5][12] - HVP delivery device revenues declined by 16.7% year-on-year to $99 million, primarily due to a prior year incentive payment [13] - Contract manufacturing segment revenues were $157 million, growing by 4.9% organically, supported by self-injected devices for obesity and diabetes [10][15] Market Data and Key Metrics Changes - Biologics revenue was $329 million, up 8.3% organically, while pharma revenue rose 1.4% to $183 million [14] - GLP-1 elastomers accounted for 9% of total company sales, indicating strong growth in this area [6][40] Company Strategy and Development Direction - The company is focused on expanding its HVP components business, particularly through GLP-1s and Annex 1 upgrades, which are expected to drive long-term growth [19][41] - The company is also working on optimizing its manufacturing network and consolidating operations to improve efficiency [67][70] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of positive trends due to strong execution and improving market conditions [21][58] - The company anticipates continued demand for HVP components and expects to mitigate tariff-related costs in 2025 [17][72] Other Important Information - The company has made notable executive appointments, including a new CFO and CTO, to strengthen its leadership team [5] - The company is ramping up production in its Dublin facility, expecting to add approximately $20 million in revenue next year [20][48] Q&A Session Summary Question: Long-term growth prospects for 2026 - Management believes the key drivers for growth are HVP components, biologics, and GLP-1s, with a foundation laid for double-digit growth [23][26] Question: Sustainability of HVP components growth - Management is confident in the momentum of HVP components, expecting low to mid-teens growth in Q4 [25][27] Question: CGM contract and backfill visibility - Management is engaged in discussions with customers to identify replacement business for the CGM contract, expecting healthy revenues and margins [30][32] Question: Headwinds and tailwinds for high-value components in 2026 - Management identified GLP-1s and Annex 1 as tailwinds, while timing of new drug approvals could present headwinds [38][41] Question: Capital allocation priorities - The company is focused on investing in high-value product components while maintaining a strong balance sheet and improving free cash flow [68][74]